

ABDUL LATIF JAMEEL HEALTH

Shaping **the future** of next generation **healthcare**

aljhealth.com

Abdul Latif Jameel  HEALTH

1945 - 2020
75
YEARS



ABDUL LATIF JAMEEL HEALTH

Working in collaboration with world-leading medical partners and investing in the brightest new health-technology companies, we are leveraging our experience and expertise to accelerate delivery of practical, affordable and more inclusive healthcare solutions across emerging economies.



Contents

1.	Access	09
2.	Innovation	21
3.	Partnerships	26
4.	Investments	32
5.	Opportunity	38
6.	Talk to us	41

ABDUL LATIF JAMEEL HEALTH

Abdul Latif Jameel Health is a multinational business guided by a clear purpose and clarity of vision. Founded in 2020 by the Jameel Family, this new venture is an urgent commercial response to the ongoing global disparity in access to modern medical care, notably across the emerging economies of the developing world.

Today, we are experiencing seismic change across many regions of the world; change driven by rising populations, urbanization and progressive economic development.

This has led to an exponential growth in the size of healthcare markets, as the sector expands to meet an increasingly urgent demand.

Abdul Latif Jameel Health is backed by Abdul Latif Jameel, one of the world's most respected family businesses. Established in 1945, Abdul Latif Jameel now employs over 11,000 people, across multi-sector interests, in over 30 countries. This heritage means Abdul Latif Jameel Health is uniquely placed to realize the many exciting opportunities ahead and deliver game-changing, real-world solutions. We will do this by leveraging existing relationships and

experience, forging new partnerships, and always working to find future-guided outcomes to answer healthcare needs where others may not.

Abdul Latif Jameel Health is committed to adding real, tangible value, not only to all our business partner relationships, but just as importantly to the communities in which we operate.

We strongly believe in the principle of being a purpose-led business and strive to build on the philosophy of our Founder, the late Sheikh Abdul Latif Jameel.

That is to work closely with our stakeholders, to ensure we always deliver on our promises, to realize our vision of accelerating access to modern healthcare... for those who need it most.

ABDUL LATIF JAMEEL HEALTH AND COMMUNITY JAMEEL

The name Jameel is not new to the health sector - for over 75 years, the spirit of our founder has guided the Jameel Family's longstanding commitment to improving life, and lives.

Abdul Latif Jameel Health is born from this commitment.

Abdul Latif Jameel Health reflects the Jameel Family's long-established commitment to innovating for a better future through Community Jameel, an international organization supporting science and technology-led solutions to global challenges.

Community Jameel and MIT co-founded the Abdul Latif Jameel Clinic for Machine Learning in Health (Jameel Clinic) in 2018, which has rapidly become the very epicenter of Artificial Intelligence and healthcare at MIT.

And more recently, the Abdul Latif Jameel Institute for Disease and Emergency Analytics (Jameel Institute) was co-founded with Imperial College London, in 2019, using novel data analytics to reduce global risk of preventable disease, including the COVID-19 pandemic, and strengthening health systems in the most fragile settings.

Our Focus

Abdul Latif Jameel Health is committed to its core principles, which inform and guide the vision we have for a more inclusive healthcare future.



Impact

Abdul Latif Jameel Health will make a meaningful and material contribution to the improvement of access to global healthcare.

We're focused on markets with unmet medical needs and driven by a desire to meet their growing healthcare demands.

The depth and quality of the relationships we aim to provide to our partners will also help their products and services make an important impact on the public health in these territories.



Quality

Quality is at the heart of everything we do, in-built at every level of Abdul Latif Jameel Health.

From distribution operations to emergent technology investments, we are realizing a vision of excellence, shared with our partners, to achieve sustainable real-world results.



Infrastructure

Through innovative solutions, we're developing infrastructure to meet the individual demands of all segments within the healthcare sector.

As Abdul Latif Jameel Health continues to grow beyond distribution services, we'll explore further opportunities across R&D manufacturing and healthcare services.

“
The cost of doing nothing
is one we cannot afford.
There are no shortcuts to a
healthier world.”

Tedros Adhanom Ghebreyesus
Director-General
World Health Organization

WORLD HEALTH
ORGANIZATION

“
Improving access to healthcare is a complex puzzle requiring a deep understanding of both needs and solutions – including technology, infrastructure, distribution.

Addressing these issues has proved to be one of society’s biggest challenges. But now more than ever, we have the technology and expertise to start making real progress.

And I’m hugely excited by the opportunities ahead.”

Fady Jameel
Deputy President and Vice Chairman, Abdul Latif Jameel

ACCESS

Accelerating access to next generation medical care for the world's most vulnerable populations

ACCESS

The time to help those most in need is now

As the healthcare gap continues to widen between nations and continents, the more pressing the need for change becomes. The world's most vulnerable populations need improved access to modern medical care today; it's vital that businesses like Abdul Latif Jameel Health engage resources to accelerate that delivery and improve life... and lives.

In January 2020, the World Health Organization (WHO) released a list of urgent global health challenges for the next 10 years.

These included making healthcare fairer, expanding access to medicines, stopping infectious diseases and preparing for epidemics.

Just 17 days later the Director-General of WHO declared the outbreak of COVID-19 to be a public health emergency of international concern.

Many people in the developed world take daily availability and access to affordable, on-demand healthcare for granted but millions across the world are denied similar access simply because of where they were born.

We are now more affluent and healthier than at any point in human history, and yet despite this, inequality appears to be growing, with whole communities denied access to adequate healthcare.

At Abdul Latif Jameel Health we believe that this access is a basic human right, and we're focused on accelerating and extending healthcare equality across the world.

ACCESS



Life expectancy

One unintended consequence of globalization and growth is an increased disparity in life expectancy between richer and poorer countries. According to recent World Health Organization figures, there is now an 18-year difference in life expectancy - and this gap is growing.

(Source: WHO)



Non-communicable diseases

Aging populations and modern lifestyles are leading to a steady increase in non-communicable diseases including cancers, Alzheimer's, diabetes, chronic respiratory and cardiovascular disease. These changes are creating a disproportionate burden on low and middle-income countries seeking to improve public health, and quickly drains the resources of poorer households.

(Source: WHO)



Affordability of healthcare

Populations across the developing world pay over half a trillion dollars in out of pocket expenses on healthcare. This unavoidable expense causes financial hardship for over 900 million people, pushing some 90 million of them into extreme poverty every year.

(Source: WHO & IMF data)



Access to essential medicines

Across the globe, up to 2 billion people have no access to essential medicines, effectively cutting them off from all the benefits modern science has made possible.

This in turn can lead to health conditions that limit their opportunities to be a productive member of society, limiting the wealth of the individual, their families and the community as a whole.

ACCESS

Proximity to primary medical care, hospitals and limited infrastructure

Shortages of doctors and other healthcare professionals, hospitals or medical laboratories greatly reduce capacity to meet healthcare needs.

Absolute population size, its dispersion across large territory and the harshness of the terrain, all contribute to the challenge of maintaining an integrated healthcare infrastructure. Limited national resources are stretched, and it becomes increasingly difficult to provide effective healthcare for everyone.

As an illustration of this, Africa averages just one doctor per 3,324 people – in Europe this number is one per 293 of the population.

Africa has over 287 million people living more than two hours transportation time away from primary medical care. Of that number, approximately 64 million are women of child-bearing age.



Distance from primary medical care in Africa



ACCESS



Low disease awareness and lack of patient support

Lack of awareness of diseases, possible treatments or available healthcare services may prevent people from seeking medical attention.

This lack of knowledge, often coupled with little or no access to the support of healthcare professionals, can also lead to poor adherence to prescribed treatments and reduce clinical effectiveness.



National spending constraints

Population growth, aging, higher rates of chronic disease such as cancer and a rising awareness of disease and diagnosis are all driving increased demand for healthcare worldwide.

These demands are putting further strain on national budgets already facing numerous economic pressures, a difficult situation amplified across emerging economies.



Basic access to emergency healthcare services

It's a sobering thought that about half of all deaths and a third of disabilities in low and middle-income countries could be avoided if the entire populations had ready access to emergency healthcare services and infrastructure.

Harnessing key trends and innovation to drive success

Core to Abdul Latif Jameel Health's vision is the constant monitoring of emerging global trends in the health sector – from regulation and policy, to innovations in technology, pharmacology, therapeutics, device development, diagnostics and relevant business models.

We then seek to maximize the opportunities these trends open up, enabling us to further our goal of working with relevant partners to accelerate the introduction of modern medical care into growing markets and developing economies.


ACCESS



Technology adoption

The rapid innovation cycle in global health technology - including Artificial Intelligence, therapeutics, medical devices and regenerative medicine - presents significant opportunities.

That's why we're working with the Jameel Investment Management Company (JIMCO) – the global investment arm of the Jameel Family – through the dedicated JIMCO Life Sciences Fund, to invest in emerging ideas and breakthrough thinking to drive rapid commercialization, allowing us to connect those businesses to new growth opportunities.



ACCESS



Global health security

Individual countries have different internal health security protocols, designed to protect the population, their healthcare systems and society itself.

Looking outwards, each country also has regulations to restrict disease from passing easily from one population to the next. On both fronts, the COVID-19 pandemic has demonstrated how important these health security measures are.

As a key player across developing markets, we are uniquely positioned to help our partners understand these different health security approaches, in doing so opening up new opportunities, and advancing our ambition to expand access to affordable modern healthcare.



Maturing regulatory environment

Previously a key barrier to market entry, governments in developing economies are now actively seeking to fast-track access to healthcare, increasing momentum for more transparent regulation, creating clarity for businesses to enter new markets.

Improvements include faster approval processes for new medicines and healthcare technologies, as well as more structured clinical guidelines.

This is already having a significant impact on drug and device filing, registration, market authorization and licensing arrangements.

Abdul Latif Jameel Health is ready to navigate these opportunities, benefiting our partners and the communities where we have a presence.




Patient centricity

Put simply, patient centricity means putting the patient first throughout their healthcare experience, treating them with respect and compassion to achieve better outcomes.

This approach highlights the importance of patient education and support programs designed to raise awareness, giving individuals the knowledge they need to prioritize their own wellbeing.

We are ready to play our part in empowering people to engage with their own health management.

ACCESS



Expansion of healthcare coverage

Governments around the world are increasingly committed to developing universal healthcare policies.

At the same time, growing consumer demand for health insurance coverage continues to drive innovative funding models.

Together, this requires an expansion in the role of public-private partnership models to create truly affordable access to healthcare provision.

Our experience and expertise allows us to play a key enabling role in this ever changing, fast-paced marketplace.



Healthcare localization

Tailoring health solutions to local market requirements, factoring in lifestyle, disease profile, infrastructure and regulation, is a key pre-requisite for success.

Increasing government endorsement and incentives to promote local manufacturing are driving this momentum and fueling rising investment.

We are continually fostering new networks of local partnerships across the world, helping us to localize our vision to develop tangible and sustainable solutions relevant to individual markets.

ACCESS

“We know the great task before us. We need *all hands, on deck*. We need to move together, leaving no one behind.”

Antonio Guterres
Secretary General
United Nations

ACCESS



“We’re partnering with those who share our vision for life - and lives – by accelerating accessibility to healthcare in areas of the world with unmet needs and that present a sustainable opportunity – where we can add tangible value to both the community and for our partners.”

Akram Bouchenaki
Chief Executive Officer
Abdul Latif Jameel Health

INNOVATION

INNOVATION

From targeted investments to implementing real-world solutions, we're driven by innovation in everything we do

INNOVATION

Constantly **evolving** in the pursuit of real-world health solutions

As we actively invest in innovative, early-stage and breakthrough ventures and technology - from pharmaceuticals and vaccines to cutting-edge medical technology - aiming to positively shape the future of health, so Abdul Latif Jameel Health constantly strives to advance its capabilities across all segments of the healthcare industry.

We are fast developing expertise across medical device, pharmaceutical and diagnostics distribution, always working to help accelerate access to modern medical care and address unmet medical needs in high growth markets.

We also offer fully integrated, bespoke business solutions designed around the needs of our partners, taking their products from registration to regulatory certification; from distribution to promotion.

When identifying an opportunity we consider what health solution that technology or partnership will rapidly bring to market, and how we can add value.

We have already collaborated with innovators, global market leaders, investors, healthcare providers and government entities who share our vision.


INNOVATION



Registration and regulatory solutions

New market entry requires understanding and management of complex local regulations and practices. We have experience across a range of solutions, including:

- Pharmaceutical and device filing and registration
- Marketing and promotional authorization
- Regulatory approval and certification
- Licensing



Logistics and distribution solutions

We have logistics and distribution expertise across many of the world's largest developing markets and a network of trusted partners beyond. Our range of services includes:

- Wholesale export depository
- Distribution of products and samples
- Product localization through secondary packing

INNOVATION



Promotion and marketing

Raising awareness to encourage the trial of new technologies and therapies requires targeted dialogue and communication at a local level. Our specialist knowledge includes:

- Design and implementation of marketing strategies
- Sales and new product representation
- Managing tender opportunities
- Educating the medical community, patients and the wider population



Pharmacovigilance solutions

In-market pharmacovigilance is critical to ensure export success and market approval. Our team can help navigate the local requirements by delivering:

- Solutions to assess and monitor pharmaceutical effects
- Workflow solutions to integrate with both regulatory and partner surveillance systems

INNOVATION

Progress is not measured by national or global averages, but by how well the health of the poor improves. If we miss the poor, we miss the point.

Dr Margaret Chan
Director General
World Health Organization, 2006-2017

We're investing in innovative, early-stage and breakthrough technologies, aiming to drive progress in positively shaping the future of health and increase the inclusivity of healthcare as a real world deliverable.

Akram Bouchenaki
Chief Executive Officer
Abdul Latif Jameel Health

PARTNERSHIPS

PARTNERSHIPS

Working in partnership with pioneering organizations to redefine the future of global health

PARTNERSHIPS



We're working with the best to achieve healthcare world-firsts

Abdul Latif Jameel Health is constantly working with a broad range of organizations to provide world leading treatments directly at point of need. As we continue to grow, expanding our portfolio of collaborations across developing technologies will allow us to export our vision for accelerated access to healthcare across much wider markets.

PARTNERSHIPS



Established in Japan in 2004, Cyberdyne are world-leading pioneers of Artificial Intelligence-robotic solutions including the robot exo-skeleton, Hybrid Assisted Limb (HAL)®

We were the first to introduce HAL® and Cybbernycs Therapy into Saudi Arabia, at the Abdul Latif Jameel Rehabilitation Hospital, Jeddah.

These remarkable advances help enable spinal injury patients to regain use of their limbs.

This successful relationship has since expanded significantly to include distribution agreements across the GCC states and beyond, establishing the hospital as an important regional training center.



Japanese immunology, biochemistry and healthcare pioneer, Cellspect, has developed highly portable, point-of-care-testing (POCT) that enable multiple blood testing parameters to be screened for simultaneously. Basic biochemical tests such as 'sugar metabolism', 'lipid' and 'liver function' can be easily measured with just a single droplet of blood from the patient's finger, and the device itself, in a simple to use, compact and portable form for ease of deployment and use in remote areas and rural settings.

In 2019, we began a collaboration with Cellspect to speed up the delivery of these low-cost, POCT devices to developing markets.

We focused on regions where these innovative, technological solutions would deliver the greatest immediate impact.



With 3.6 billion yen capital (US\$ 32.9 million), Japanese investment platform JOMDD specializes in investing and commercializing innovative new technologies in medical device development. Their mission goes beyond the solely commercial, driven by the belief – shared by Abdul Latif Jameel Health – that the global population should have access to the best possible healthcare.

In early 2020, Abdul Latif Jameel Health and JOMDD announced an incubator partnership to bring innovative Japanese medical device technology to developing markets.

Combining the worldwide network of Abdul Latif Jameel with the business development capability of JOMDD, Abdul Latif Jameel Health will collaborate with innovative Japanese health companies commercialization of new technologies.



PARTNERSHIPS



American based EVELO Biosciences is developing oral biologics that act on cells in the small intestine to produce systemic therapeutic results.

These therapies have the potential to improve the lives of people with inflammatory diseases including potentially some cancers. This approach also has the potential to speed up the discovery of new drugs, at the same time improving the probability of success and decreasing cost.

EVELO Biosciences and Abdul Latif Jameel Health announced a strategic collaboration in early 2021 to develop and commercialize novel therapy EDP1815 for inflammatory diseases and COVID-19, across select developing markets serving over 1.7 billion people.



Founded in 2017, Cellarity is a first-of-its-kind therapeutics company discovering and developing medicines by studying and altering cell behaviors.

Cellarity developed a powerful, generalizable platform harnessing single-cell technologies and machine learning to unveil the network state of a given cell, defining the cell's behavior. This platform digitizes and quantifies cellular behaviors, unravels the network dynamics that govern those behaviors, and generates medicines that can direct them.

In 2021, Abdul Latif Jameel Health participated in a US\$ 123 million Series B funding round to pioneer this ground breaking new approach to drug discovery.



According to the latest data available the 10-year survival rate was 85.9% for AVNeo compared to less than 80% for alternative procedures.

Using the patient's own pericardial tissue, this new technique provides an exciting advance in open heart surgery for all age groups, with studies showing that some patients are now able to stop taking medications just six months after their procedure.

In 2021, Abdul Latif Jameel Health in collaboration with the Saudi Arabian Ministry of Health, launched a pioneering new medical procedure for the surgical reconstruction of the aortic heart valve, making Saudi Arabia the first country in the Gulf region to use this innovative AVNeo technique.

(Source: Journal of Thoracic and Cardiovascular Surgery 2018)



PARTNERSHIPS



Based in Japan, Melody International has produced a unique medical instrument, the Mobile Fetal Monitor iCTG - Melody i.

It's a small, smart, mobile fetal monitoring device, allowing doctors to stay up to date with problem pregnancies swiftly and remotely. The wireless system includes a fetal heart monitor, uterine contraction monitor, and a tablet. The built-in speaker in the transducer means the device can also be used as a fetal doppler. Data is sent to a smartphone and stored on a server, so maternal and fetal conditions can be checked remotely even at distant locations, streamlining and simplifying the process of fetal care.



Holoeyes is revolutionizing healthcare communication and surgical training with cutting-edge VR technology, a synthesis of medicine and technology that is dramatically enhancing diagnosis and understanding.

The company provides VR and MR services to the healthcare sector and to leading medical education institutions. Their Holoeyes XR virtual reality software is now enhancing medical treatments, procedure planning and education. The 3D data generated is converted and stored in a digital library, where it is available for browsing, allowing clients to share experiences, mark achievements, perform searches and review past experiences.



Currently, 4.7 billion people around the world lack access to vital ultrasound imaging. Butterfly has invented a system that puts ultrasound on a chip, works via an app, and created the world's first handheld, ultra-portable, whole-body imager for less than US\$ 2,000.

A fusion of semiconductors, Artificial Intelligence and cloud technology has created an ultrasound device set to usher in a new era in healthcare, with huge implications for remote populations across the world.



PARTNERSHIPS



COVID-19 is taking so much from us. But it's also giving us something special – the opportunity to come together as one humanity – to work together, to learn together, to grow together.

Tedros Adhanom Ghebreyesus
Director General
World Health Organization, 2017-present

PARTNERSHIPS

“
We are entering a new era of network biology with the ability to deeply understand cellular processes and to create medicines with much more predictability and intentionality.
”

Fabrice Chouraqui
CEO-Partner, Flagship Pioneering
CEO, Cellarity

INVESTMENTS

Targeted investments redefining the very future of health with cutting-edge technologies and breakthrough thinking

INVESTMENTS

By looking **beyond today** and investing in the **future**, we help **shape the future** we want to see



Working closely with the Jameel Investment Management Company ([JIMCO](#)) and the dedicated [JIMCO Life Sciences Fund](#), Abdul Latif Jameel Health is actively investing in the start-up healthcare companies that will help form the future of medical treatments.

Through a rigorous selection procedure, we're targeting investments into innovative technological and scientific advances, breakthrough thinking and new business and service delivery models across the entire healthcare spectrum.

We're already invested in, and working alongside, exciting new companies opening up opportunities across medical devices and tech, diagnostics, vaccines, therapeutics, pharmaceuticals, and ground-breaking technologies including Artificial Intelligence and machine learning.

INVESTMENTS



American based Evelo Biosciences is developing oral biologics that act on cells in the small intestine to produce systemic therapeutic results.

These therapies have the potential to improve the lives of people with inflammatory diseases including potentially some cancers. This approach also has the potential to speed up the discovery of new drugs, at the same time improving the probability of success and decreasing cost.

Evelo Biosciences and Abdul Latif Jameel Health announced a strategic collaboration in early 2021 to develop and commercialize novel therapy EDP1815 for inflammatory diseases and COVID-19, across select developing markets serving over 1.7 billion people.

Evelo received equity investment to develop and manufacture EDP1815, whilst Abdul Latif Jameel Health will be responsible for regulatory submissions and commercialization activities in agreed regions.

 WATCH VIDEO



Founded in 2017, Cellarity is a pioneering therapeutics company discovering and developing medicines by altering cell behavior.

Bringing together experts from therapeutic development, genomics technology, systems biology, digital science and Artificial Intelligence, they are innovating new ways to collaborate skills to usher in a new era in drug development. Their focus is to create breakthrough medicines to treat a wide range of diseases.

Cellarity's medicines are developed to address disease at the level of the cell itself and are not aimed at single molecular targets, the approach pursued in many traditional drug discoveries.

In 2021, Abdul Latif Jameel Health participated in the Series B US\$ 123m funding round.

 WATCH VIDEO



EQRx is committed to making innovative medicines at dramatically lower prices for the benefit of people and society.

By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the company seeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before.

This vision for more inclusive healthcare for all, is fully aligned with that of Abdul Latif Jameel Health and in 2021, this led to its participation in the US\$ 500m Series B funding round, through the JIMCO Life Sciences Fund.

 WATCH VIDEO

INVESTMENTS

laronde

Laronde was founded in 2017, and is pathfinding a platform that offers a completely novel way of modulating human biology.

Endless RNA™ (eRNA), is a uniquely engineered RNA that can be programmed to express diverse therapeutic proteins inside the body. It is persistent, non-immunogenic, allows for repeat dosing, and offers flexibility in formulation and delivery.

INVESTMENTS

Targeted investments in innovative start-ups are leading to breakthrough technologies that help make healthcare more affordable and more practical to use in remote regions, driving inclusivity in health for all.

Bruce Currie
JIMCO Life Sciences Fund

Every time we invent something, we make it easier to invent something else.

Erik Brynjolfsson
Senior Fellow
Stanford Institute for Human-Centered
Artificial Intelligence

OPPORTUNITY

Our experience enables our agility and flexibility to respond to change – and realize opportunities

OPPORTUNITY

Developing new markets by unlocking access to affordable healthcare

Abdul Latif Jameel Health is at the start of an exciting journey, a journey to build a world-leading international medi-tech distribution company. Our global footprint and heritage are already attracting the best talent and partners from science, biotech, academia, commerce, and industry... but we've only just begun.

Our aim is to leverage the latest advances in health-tech to provide affordable healthcare where it's needed most. The opportunity to make a real difference is now, so we've already established access to growing markets including Latin America, Africa, the Middle East, South and South East Asia, Japan and China.

We've also partnered with innovative organizations, with a particular focus on helping to bring portable point of care testing to developing markets and assisting in the commercialization of cutting-edge medical devices.

Of course, we'll face real challenges along the way, with fragmentation across the globe and many healthcare systems where affordability remains the main barrier to access. However, we're certain that through targeted investments and our distribution expertise, we can develop regional opportunities, making markets more accessible to global pharmaceutical, medical device, therapeutics and diagnostics OEMs, empowering health-tech entrepreneurs to bring their products to these markets.

Through real-world actions, we believe the Abdul Latif Jameel Health vision will soon become a reality.

With today's meeting of fast-growing healthcare markets, regulatory and government reforms and our pipeline of innovative solutions and distribution expertise, Abdul Latif Jameel Health is perfectly placed to help accelerate access to next generation medical care for the world's most vulnerable populations.

OPPORTUNITY

It is completely unacceptable that half the world still lacks coverage for the most essential health services.

Dr Tedros Adhanom Ghebreyesus
Director-General
World Health Organization, 2017-present

Access to healthcare must be seen as an undeniable basic human right, irrespective of where people live or economic means – like water or shelter.

Although a difficult and multifaceted problem, Abdul Latif Jameel Health is determined to be part of the solution.

Fady Jameel
Founder, Abdul Latif Jameel Health
Deputy President and Vice Chairman, Abdul Latif Jameel

Talk To Us

We invite you to partner with Abdul Latif Jameel Health

We're ready to invest in early-stage market innovators and collaborate with established industry leaders. We want to partner with the extraordinary, companies and individuals who share our vision for a healthier future. Together we can establish new markets and deliver affordable, next generation medical care to those who need it most.

To start the conversation, please contact us at

info@aljhealth.com

Abdul Latif Jameel Health
Le Metropole
1 Avenue des Citronniers
MC 98000 Monaco

Copyright Notice and Disclaimer

© Meddist Company Ltd. (Abdul Latif Jameel Health). All rights fully reserved. The Abdul Latif Jameel name, and the Abdul Latif Jameel logotype and pentagon-shaped graphic are trademarks, or registered trademarks of Abdul Latif Jameel IPR Company Limited.

The term "Abdul Latif Jameel" refers broadly to several distinct, separate and independent legal entities. Abdul Latif Jameel is not itself a corporate entity, association or conglomerate run by an overarching parent company but merely refers to a group of distinct and wholly separate legal entities that are collectively referred to as Abdul Latif Jameel. Abdul Latif Jameel is not a corporate group as defined in section 5(1161) of the Companies Act 2006.

This document may contain forward-looking statements. Forward-looking statements are statements regarding matters other than historical fact, such as future results, events, activities, developments or circumstances or the beliefs, plans or expectations of Abdul Latif Jameel Health or Abdul Latif Jameel entities or their respective managements.

Forward-looking statements often can be identified by the use of words such as 'expect', 'project', 'anticipate', 'plan', 'estimate', 'believe', 'predict', 'intend', 'potential', 'possible', 'probable', 'likely', 'forecast', 'guidance', 'outlook', 'goal', 'target', 'may',

'will', 'should' or 'could' or other similar terms or phrases. However, the absence of such words does not mean that a particular statement is not forward looking.

Forward-looking statements are based on expectations and assumptions at the time of such statements and are subject to numerous risks and uncertainties, many of which are outside the control of Abdul Latif Jameel Health or Abdul Latif Jameel entities. Should any of such expectations or assumptions prove incorrect, or should any of such risks or uncertainties materialize, actual future results, events, activities, developments or circumstances may differ materially from those expressed in or implied by forward-looking statements.

Further, any forward-looking statement speaks only as of the date on which it is made, and neither Abdul Latif Jameel Health nor Abdul Latif Jameel assumes, and hereby disclaims, any obligation to correct or update any forward-looking statement, whether as a result of new information, future events or otherwise. All forward-looking statements made by Abdul Latif Jameel Health, Abdul Latif Jameel, or by any person on behalf of any of them, whether communicated in writing, electronically or orally, are qualified in their entirety by the foregoing cautionary statements.

aljhealth.com



Abdul Latif Jameel  HEALTH

1945 - 2020

YEARS